We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ANAB market cap is 515.72M. The company's latest EPS is USD -6.1136 and P/E is -3.15.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.29M | 6.81M | 1.37M | 3.46M | 3.32M |
| Operating Income | -29.63M | -25.97M | -44.4M | -40.14M | -37.73M |
| Net Income | -33.5M | -26.41M | -44.26M | -39.85M | -37.31M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 8M | 75M | 63.18M | 10.29M | 17.16M |
| Operating Income | -107.43M | -23.88M | -56.81M | -115.15M | -164.41M |
| Net Income | -97.34M | -19.93M | -57.8M | -128.72M | -163.62M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 618.5M | 610.38M | 551.79M | 517.1M | 487.33M |
| Total Liabilities | 340.88M | 348.28M | 360.7M | 368.65M | 366.94M |
| Total Equity | 277.62M | 262.1M | 191.09M | 148.45M | 120.38M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 435.2M | 416.55M | 643.07M | 610.38M | 452.39M |
| Total Liabilities | 30.19M | 19.82M | 286.64M | 348.28M | 364.29M |
| Total Equity | 405.01M | 396.73M | 356.43M | 262.1M | 88.1M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -62.91M | -73.59M | -24.57M | -49.98M | -86.45M |
| Investing | -416.34M | -394.85M | 85.4M | 64.94M | 95.58M |
| Financing | 42.07M | 44.02M | -37.57M | -51.07M | -54.14M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -69.52M | -14.16M | -45.92M | -73.59M | -120.8M |
| Investing | 131.43M | 94.48M | 38.84M | -394.85M | 144.75M |
| Financing | -4.49M | -879k | 252.3M | 44.02M | -59.3M |
| Market Cap | 515.72M |
| Price to Earnings Ratio | -3.15 |
| Price to Sales Ratio | 30.04 |
| Price to Cash Ratio | 14.33 |
| Price to Book Ratio | 5.85 |
| Dividend Yield | - |
| Shares Outstanding | 26.76M |
| Average Volume (1 week) | 312.46k |
| Average Volume (1 Month) | 355.53k |
| 52 Week Change | -10.91% |
| 52 Week High | 27.50 |
| 52 Week Low | 13.36 |
| Spread (Intraday) | 3.23 (15.38%) |
| Company Name | AnaptysBio Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.anaptysbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
